<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="ribavirin/PMC7318677/results/search/drugs/results.xml">
  <result pre="of RNA. Previously known nucleic acid catalysts attached fluorescently labeled" exact="adenosine" post="or guanosine derivatives through 2′,5′‐branched phosphodiester bonds to the"/>
  <result pre="units through a hydrolytically more stable phosphonate ester linkage. The" exact="tenofovir" post="transferase ribozymes were identified by in vitro selection and are"/>
  <result pre="RNA. antiviral nucleoside analogues in vitro selection ribozymes site-specific RNA labeling" exact="tenofovir" post="Funding European Research Council 10.13039/501100000781 682586 fig-count: table-count: ref-count:"/>
  <result pre="applications.7 Recently, we reported the FH14 ribozyme to attach N6‐labeled" exact="adenosine" post="to specific internal 2′‐OH groups through 2′,5′‐phosphodiester bonds.8 This"/>
  <result pre="as substrate and a structured RNA library with a bulged" exact="adenosine" post="as target site for labeling. The resulting ribozymes proved"/>
  <result pre="enzymes by attachment of non‐natural nucleotide analogues. Specifically, we considered" exact="tenofovir" post="diphosphate as a ribozyme substrate. Tenofovir is an FDA‐approved"/>
  <result pre="TDF),12 or phosphonamidate (tenofovir alafenamide, TAF).13 Upon release by esterases," exact="tenofovir" post="is phosphorylated by cellular nucleotide kinases to tenofovir diphosphate,"/>
  <result pre="by esterases, tenofovir is phosphorylated by cellular nucleotide kinases to" exact="tenofovir" post="diphosphate, which is the active drug metabolite that acts"/>
  <result pre="1 Ribozyme‐catalyzed site‐specific labeling of an RNA target using N6‐biotinylated" exact="tenofovir" post="diphosphate (biotin‐Ten‐DP), forming a phosphonate ester linkage with the"/>
  <result pre="a phosphonate ester linkage with the 2′‐OH of the bulged" exact="adenosine" post="(red) that is located in between two Watson–Crick base‐paired"/>
  <result pre="5′‐GGACAUACUGAGCCUUCAA. The previously identified adenylyl‐transferase ribozyme FH148 was tested with" exact="tenofovir" post="diphosphate, but it was not able to use the"/>
  <result pre="diphosphate, but it was not able to use the acyclic" exact="adenosine" post="derivative as a substrate for RNA labeling (Figure S1). Therefore,"/>
  <result pre="form a phosphonate ester with the 2′‐OH of the target" exact="adenosine" post="using N6‐modified tenofovir diphosphate as substrate (Figure 1). Using Watson–Crick"/>
  <result pre="ester with the 2′‐OH of the target adenosine using N6‐modified" exact="tenofovir" post="diphosphate as substrate (Figure 1). Using Watson–Crick base‐paired binding arms,"/>
  <result pre="Using Watson–Crick base‐paired binding arms, the ribozymes target a bulged" exact="adenosine" post="in the RNA of interest and catalyze labeling of"/>
  <result pre="interest and catalyze labeling of its 2′‐OH group. A biotinylated" exact="tenofovir" post="substrate was used for a bead‐based in vitro selection strategy"/>
  <result pre="procedure (with N6‐biotin‐ATP that resulted in FH ribozymes).8 The N6‐biotinylated" exact="tenofovir" post="diphosphate (biotin‐Ten‐DP) was synthesized from 6‐chloropurine in 7 steps"/>
  <result pre="for fluorescence spectroscopy or RNA imaging. In this respect, fluorescent" exact="tenofovir" post="analogues or derivatives with bioorthogonal functional groups for conjugation"/>
  <result pre="desirable as ribozyme substrates. Therefore, the respective N6‐hexynyl and N6‐azidohexyl‐modified" exact="tenofovir" post="diphosphates were synthesized and used for the attachment of"/>
  <result pre="fluorescein or Cy5 fluorophores through Cu‐catalyzed azide–alkyne cycloaddition (Scheme S2). Unmodified" exact="tenofovir" post="diphosphate (Ten‐DP) was tested as a reference.20 Gratifyingly, all"/>
  <result pre="fluorescently labeled RNA after 22 h. Figure 4 a) Structures of unmodified" exact="tenofovir" post="diphosphate, and analogues with N6‐hexynyl (alkyne) and N6‐azidohexyl (azide)"/>
  <result pre="mean of triplicates with standard error. Yields with fluorophore labeled" exact="tenofovir" post="analogues after 22 h. b) Labeling of mutated target RNAs with"/>
  <result pre="scope of FJC9. Next, the RNA substrate scope of the" exact="tenofovir" post="transferase ribozymes was investigated. Transition and transversion mutations were"/>
  <result pre="established RNA‐catalyzed labeling of RNA using the antiviral nucleoside analogue" exact="tenofovir" post="as scaffold for bioorthogonal ribozyme substrates. This work also"/>
  <result pre="Acids2015, 4, e230.25734917 18FJ is our laboratory nomenclature for the" exact="tenofovir" post="transferase ribozyme selection, and the numbers 1 and 8"/>
  <result pre="R.Miller, T.Wei, C. J.Fields, P.Sheng, M.Xie, RNA2018, 24, 1871–1877.30201850 20The" exact="tenofovir" post="analogues synthesized in this study were used as racemic"/>
  <result pre="revealed similar activity of FJ1 with enantiomerically pure and racemic" exact="tenofovir" post="diphosphate substrate (Figure S15)."/>
 </snippets>
</snippetsTree>
